In June 2017, Transcell shareholders agreed to focus it’s disruptive drug discovery pursuits in Oncology vertical with the team’s early breakthrough data on certain druggable molecules discovered, as a spin out (Transcell Oncologics). The research on predictive real time donor and patient based progenitor cellular platforms dates back to 2013 while access to nature inspired novel macrocyclic small molecules/toolbox to 2014.